Navigation Links
Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
Date:12/10/2008

ST. PAUL, Minn., Dec. 10 /PRNewswire/ -- Prime Therapeutics LLC (Prime) announces that it has been chosen by Blue Cross and Blue Shield of Montana (BCBSMT) to provide commercial pharmacy benefit management services, beginning January 1, 2009.

Prime will provide pharmacy benefit services to more than 175,000 BCBSMT members enrolled in health plans that include prescription drug coverage. The three-year contract covers a range of pharmacy benefit services including: claims processing, clinical programs, formulary administration, manufacturer contracting, member services, pharmacy network management, prescription mail service and specialty services. In addition, Prime will continue to provide Medicare Part D administration for BCBSMT, a service it has been providing for the health plan since 2006.

Key factors influencing the selection of Prime included the Blues-owned PBM's ability to provide supreme attention to member services and its integrated medical and pharmacy capabilities as well as its industry-unsurpassed customer satisfaction ratings. "Prime's reputation for strong customer service and pharmacy expertise were important factors in our decision," said Blue Cross and Blue Shield of Montana President and Chief Executive Officer Sherry Cladouhos. "As a Blues-owned PBM, we are relying on Prime to deliver the service-oriented, reliable programs Blue Cross and Blue Shield of Montana strives to offer in all our services."

"Prime welcomes Blue Cross and Blue Shield of Montana's business. Our operational scalability and innovative pharmacy approach positions us to efficiently add Blue Cross and Blue Shield of Montana to our growing family of Blues clients," said Tim Dickman, Prime's President and Chief Executive Officer. "The value of an integrated, in-house pharmacy continues to provide the aligned, full service solution that our Blues partners are seeking."

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 14.6 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 10 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at http://www.primetherapeutics.com.

Blue Cross Blue and Shield of Montana, an independent licensee of the Blue Cross and Blue Shield Association, is Montana's leading not-for-profit health services corporation. Headquartered in Helena, MT, it has conducted business for more than 65 years exclusively in Montana. It serves more than 240,000 members across the state and another 70,000 nationwide through BlueCard. More information is available at http://www.bcbsmt.com.


'/>"/>
SOURCE Prime Therapeutics LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Lab Series(R) Skincare For Men Spa Indulges the 2007 Primetime Emmy(R) Nominees at the Sofitel(R) Los Angeles
3. Prime Access Creates Groundbreaking Ads Targeting Urban Teens for the White Houses National Youth Anti-Drug Media Campaign
4. Prime Therapeutics Announces URAC Accreditation
5. Prime Minister views innovative health technology at Imperial College London
6. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
7. Prime Healthcare Services Acquires Centinela Hospital Medical Center
8. Activist Groups Plea to Indian Prime Minister: Rollout Second-Line AIDS Treatment!
9. Announcing Prime Vendor Contract with LIHPA
10. Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
11. Fetal Alcohol Exposure May Prime Offspring for Alcoholism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... ... management solution focused on delivering end-to-end sleep health care at scale, indicates ... literature shows that adherence rates for positive airway pressure (PAP) therapy, the most ...
(Date:7/24/2017)... BEACH, Calif. (PRWEB) , ... July 24, 2017 , ... ... ranging from food addiction to sexual abuse, and how she has overcome them. “Forbidden ... traumatic instances in her life and how she has risen above. , In “Memories,” ...
(Date:7/24/2017)... PA (PRWEB) , ... July 24, 2017 , ... ... 2030, today CURE announced that they have enrolled over 100,000 children in their ... afflicted children born every year in areas where treatment is limited or non-existent. ...
(Date:7/24/2017)... ... July 24, 2017 , ... Clinical ... MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, VA, http://www.fdanews.com/cqa , ... Increased FDA scrutiny and growing demands to track and report adverse events place ...
(Date:7/24/2017)... ... July 24, 2017 , ... On July ... was set up, and the awarding ceremony was held successfully in Beijing. The ... of the army's health system, and national Chinese medicine experts also attended the ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/10/2017)... 2017 Locus Biosciences Inc. today announced the ... development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the round ... Internet services provider, and joined by the North Carolina ... product programs targeting antibiotic resistant infections and other microbiome-related ... Dr. Rodolphe Barrangou and Dr. Charles ...
(Date:7/5/2017)... , July 5, 2017 Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... it has received approval from the Israel Securities Authority to ... (TASE). Oramed common stock will commence trading on the TASE ... the current market capitalization of the Company, it is expected ...
Breaking Medicine Technology: